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Abstract: Multidrug-resistant tuberculosis has emerged worldwide, with an increasing   incidence 
due to failure of implementation of apparently effective first-line antituberculous therapy as well 
as primary infection with drug-resistant strains. Failure of current therapy is attributed to a long 
duration of treatment leading to nonadherence and irregular therapy, lack of patient education 
about the disease, poverty, irregular supply by care providers, drug–drug interactions in patients 
coinfected with human immunodeficiency virus (HIV), inadequate regulations causing market 
overlap and irresponsible drug usage in the private sector, and lack of research, with no addi-
tion of new drugs in the last four decades. Present standards of care for the treatment of drug-
susceptible tuberculosis, multidrug-resistant tuberculosis, tuberculosis-HIV coinfection, and 
latent tuberculosis infection are all unsatisfactory. Since 2000, the World Health Organization 
(WHO) has focused on drug development for tuberculosis, as well as research in all relevant 
aspects to discover new regimens by 2015 and to eliminate tuberculosis as a public health 
concern by 2050. As a result, some 20 promising compounds from 14 groups of drugs have 
been discovered. Twelve candidates from eight classes are currently being evaluated in clinical 
trials. Ongoing research should prioritize identification of novel targets and newer application 
of existing drugs, discovery of multitargeted drugs from natural compounds, strengthening host 
factors by immunopotentiation with herbal immunomodulators, as well as protective vaccines 
before and after exposure, consideration of surgical measures when indicated, development 
of tools for rapid diagnosis, early identification of resistant strains, and markers for adequacy 
of treatment and an integrative approach to fulfill WHO goals. However, regulatory control 
over the drug market, as well as public-private partnership to use health program facilities to 
track patients and ensure completion of adequate therapy will be necessary to exploit fully the 
potential of the newer regimens to eliminate tuberculosis.
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Introduction
Drug-resistant tuberculosis is widespread and found in all countries surveyed. 
It emerges as a result of treatment mismanagement, and is passed from person to 
person in the same way as drug-sensitive tuberculosis. Multidrug-resistant tuber-
culosis is caused by bacteria that are resistant to the most effective antituberculous 
drugs, ie, isoniazid and rifampicin. There were an estimated 44,0000 new multidrug-
resistant tuberculosis cases in 2008, and 150,000 deaths from the disease. It was 
estimated that 3.3% of all new tuberculosis cases in 2009 were multidrug-resistant. 
In 2010, the largest World Health Organization (WHO) multidrug-resistant tuber-
culosis survey reported the highest rates ever of multidrug-resistant tuberculosis, Clinical Pharmacology: Advances and Applications 2011:3
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with peaks of up to 28% of new cases in some settings of 
the former Soviet Union. Many countries have developed 
plans to address multidrug-resistant tuberculosis, but the 
response globally is still inadequate. Highest absolute 
numbers of multidrug-resistant tuberculosis cases are in 
China and India, accounting for nearly 50% of the world-
wide burden.
Extensively drug-resistant tuberculosis is caused by 
bacteria that are resistant to isoniazid and rifampicin 
(ie,   multidrug-resistant) as well as all fluoroquinolones 
and any of the second-line antituberculous injectable drugs 
  (amikacin, kanamycin, capreomycin). These forms of tuber-
culosis do not respond to standard treatment comprising 
6 months of first-line antituberculous drugs, and can take 
at least two years to treat with drugs that are less potent, 
more toxic, and much more expensive. On average, 5.4% of 
multidrug-resistant tuberculosis cases have been found to 
be extensively drug-resistant, as confirmed by surveillance 
in 58 countries, and this would account for around 25,000 
cases of extensively drug-resistant tuberculosis emerging 
every year.1,2
Rifampicin is a member of the last novel class of antibiot-
ics introduced in 1963 for first-line treatment of tuberculosis. 
Drugs in this class are part of a 6-month regimen that is 
ineffective against multidrug-resistant and extensively drug-
resistant tuberculosis, and have unfavorable drug interactions 
with many antiretroviral drugs. Except for the addition of the 
fluoroquinolones as second-line therapy, nothing was added 
until 2000 (Figure 1). Since then, over 12 compounds have 
progressed to the clinical development pipeline for treatment 
of tuberculosis (Table 1). These compounds, if properly devel-
oped, have the potential to become part of a future regimen 
that could greatly improve the global effort to control tuber-
culosis.3 The potential benefits of new drugs in development 
have been investigated by a modeling study, which suggests 
that the combination of a 2-month treatment regimen that 
cures 95% of multidrug-resistant tuberculosis, a generalized 
nucleic acid amplification test for diagnosis, and a joint pre-
exposure as well as post-exposure vaccine could potentially 
reduce the incidence of the disease by 71% in 2050. Addition 
of preventive   treatment for latent tuberculosis infection to this 
regimen might reduce the incidence by 94%.4Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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Current treatment  
for multidrug-resistant tuberculosis
Multidrug-resistant tuberculosis has become increas-
ingly prevalent, and an extensively drug-resistant form 
is emerging.5 Combinations of first-line and second-line 
drugs are useful for the treatment of multidrug-resistant and 
  extensively drug-resistant tuberculosis according to results 
of drug susceptibility testing. Second-line drugs include 
aminoglycosides (kanamycin and amikacin), cycloserine, 
terizidone, ethionamide, prothionamide, capreomycin, amin-
osalicylic acid, and fluoroquinolones (including ofloxacin, 
levofloxacin, gatifloxacin, and moxifloxacin). The percent-
age of patients with multidrug-resistant tuberculosis who 
are cured is estimated to be no more than 69%, even when 
treated for more than 18 months with directly observed 
treatment.6 In 2008, only about 1% of cases of multidrug-
resistant tuberculosis were estimated to have received proper 
treatment according to the standards recommended by the 
WHO.7 Containment of the spread of multidrug-resistant 
and extensively drug-resistant tuberculosis will be extremely 
difficult without treatment regimens that are shorter, safer, 
more effective, and less expensive than those presently 
available. New drugs with novel mechanisms of action are 
needed for effective management of multidrug-resistant 
and extensively drug-resistant tuberculosis.4 One study 
documented the emergence of new forms of totally drug-
resistant bacilli among patients with multidrug-resistant 
disease. The isolation of totally drug-resistant strains from 
multidrug-resistant tuberculosis patients from different 
regions is alarming, and indicates possible dissemination 
of such strains in Asian countries.8
Ideal profile of new drug/regimen
Duration of the curative regimen must be shortened to less 
than 2 months or, ideally, to days (Figure 2). It should be 
Figure 2 TB drug regimen goal.
Abbreviation: TB, tuberculosis.
Table 1 Tuberculosis clinical development programs
Groups Compound Development stage Sponsor/coordinator
Rifamycins Rifapentine Phase ii/iii CDC TBTC, sanofi-aventis
Fluoroquinolone Gatifloxacin Phase iii european Commission; iRD; wHO/TDR; Lupin
Moxifloxacin Phase ii/iii Bayer; TB Alliance; CDC; University College London;   
Johns Hopkins University
DC-159a Preclinical Japan Anti-Tuberculosis Association,  
JATA Daiichi-Sankyo Pharmaceutical Co
Oxazolidinone Linezolid (low dose) Phase ii CDC TBTC, Pfizer, various universities
PNU-100480 Phase i Pfizer
AZD5847 Phase i AstraZeneca
Diarylquinoline TMC207 Phase ii Johnson & Johnson (Tibotec)
Nitroimidazole OPC67683 Phase ii Otsuka Pharmaceutical
PA824 Phase ii TB Alliance
Pyrrole LL3858 Phase i Lupin
Diamine SQ109 Phase ii Sequella
Dipiperidines SQ609 eBA Sequella
Capuramycins SQ641 eBA Sequella
isothiazoloquinolone ACH-702 Preclinical Achillion Pharmaceuticals
Caprazene nucleoside Caprazamycin Preclinical MCRF, Tokyo, Japan 
Lilly TB Drug Discovery initiative 
NiAiD, iDRi, Lilly, Yourencore
Benzothiozinones BZT043 eBA ePFL School of Life Sciences
imidazopyridine Q201 eBA Quro Science, inc
Riminophenazines Phenoxazine and  
asymmetrical  
riminophenazine series
eBA and Phase i institute of Materia Medica, China and Beijing  
Tuberculosis and Thoracic Tumor  
Research institute
Abbreviations: CDC, Centers for Disease Control and Prevention; TBTC, Tuberculosis Trials Consortium; TDR, Special Programme for Research and Training in 
Tropical Diseases; eBA, early bactericidal activity; MCRF, Microbial Chemistry Research Foundation; NiAiD, National institute of Allergy and infectious Diseases; ePFL, École 
Polytechnique Fédérale de Lausanne; GSK, GlaxoSmithKline; iDRi, infectious diseases research institute; wHO, world Health Organization; TB, tuberculosis.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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effective against multidrug-resistant and extensively drug-
resistant tuberculosis due to a novel mechanism of action 
and should not have cross-resistance with the classical 
regimen. It should be devoid of toxicity and have no drug–
drug interactions with antiretroviral therapies. It should be 
possible to administer once a day or intermittently by the 
oral route and must be affordable in resource-scarce regions 
with a high incidence of multidrug-resistant and extensively 
drug-resistant tuberculosis.9
Present clinical trials are testing new combinations of 
drugs for their safety and efficacy in treatment durations 
of 6 months for drug-susceptible tuberculosis, as well as 
new drugs in optimized regimens for multidrug-resistant 
tuberculosis.10 A growing pipeline of single compounds 
underscores the needs for devising and testing optimal drug 
combinations that would be suitable for treatment of tuber-
culosis in all its forms, and the necessary collaboration of 
pharmaceutical companies, academia, research institutions, 
donors, and regulatory authorities.10
New antituberculous medicines  
in the pipeline
Fluoroquinolones
Fluoroquinolones are broad-spectrum antimicrobial drugs 
that target DNA gyrase. Several members of this class 
have been used as second-line drugs for the treatment of 
multidrug-resistant tuberculosis. Gatifloxacin and moxi-
floxacin have shown better in vitro activity than ofloxacin 
and ciprofloxacin against Mycobacterium tuberculosis.11–13 
They have little interaction with cytochrome P450 (CYP), 
so could be coadministered with antiretroviral drugs 
  without fear of drug–drug interactions. Also, they have the 
potential to shorten the duration of the regime by improved 
sterilization activity.14 The fluoroquinolones have been safe 
and well tolerated in most of the studies involving drug 
combination trials for earlier sputum culture conversion,15 
although gatifloxacin has been shown to increase the risk 
of hospitalization for dysglycemia in patients with and 
without diabetes.16 Use of fluoroquinolones should be 
avoided in patients with risk factors for prolongation of the 
QTc interval or tendinopathy. All fluoroquinolones should 
be used with caution in patients with a history of seizure 
disorders, and may cause phototoxicity and Clostridium 
difficile-associated diarrhea.16
Gatifloxacin
A trial was conducted by the South African Medical 
Research Council in Durban, South Africa, in patients 
with newly diagnosed pulmonary tuberculosis with and 
without HIV coinfection to measure the antituberculous 
activity of gatifloxacin in the first 2 months of therapy 
when compared with the standard treatment recommended 
by the WHO, and two other similar regimens containing 
either ofloxacin or moxifloxacin. Treatment with either the 
gatifloxacin-containing or moxifloxacin-containing regi-
men was shown to be significantly more active than either 
the standard regimen or the ofloxacin-containing regimen 
after 2 months of therapy.13 Phase III trials are in progress 
investigating if treatment of drug-susceptible tuberculosis 
can be shortened to 4 months by substitution of gatifloxacin 
for ethambutol.4
Moxifloxacin
Moxifloxacin improves culture conversion in the initial phase 
of tuberculosis treatment when substituted for ethambutol.17,18 
Substitution of moxifloxacin for isoniazid resulted in a small 
but statistically nonsignificant increase in culture negativity 
at week 8.19
Oxazolidinones
Oxazolidinones exert their antimicrobial activity via inhibi-
tion of protein synthesis by binding to the 70S   ribosomal ini-
tiation complex.20 These compounds have a broad   spectrum 
of   activity against anaerobic and Gram-positive aerobic 
bacteria, as well as mycobacteria.21
Linezolid
Linezolid is the first approved oral antibiotic of the 
  oxazolidinone class, and has demonstrated in vitro activity 
against both drug-susceptible and drug-resistant isolates 
of M. tuberculosis without showing cross-resistance with 
the standard antituberculous agents.22 Linezolid has been 
used off-label in combination regimens to treat multidrug-
resistant tuberculosis, but its precise contribution to the 
efficacy of such combinations is unclear. However, one 
case series has reported a successful outcome in extensively 
  drug-resistant tuberculosis, with manageable side effects.23,24 
In a   retrospective study, the majority of patients with 
multidrug-resistant tuberculosis on linezolid had favorable 
treatment outcomes, although treatment was complicated by 
adverse events that required extensive clinical management.25 
Long-term use of linezolid has been associated with cumu-
lative toxicity, including peripheral and optic neuropathy.26 
A low-dose trial with   linezolid 300 mg/day proved useful 
for increasing the chances of culture conversion in the 
treatment of patients with intractable multidrug-resistant Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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or extensively drug-resistant tuberculosis, and had a lower 
incidence of neurotoxicity compared with a 600 mg/day dose 
of linezolid.27 Further research is underway using a 300 mg 
dose of linezolid for multidrug-resistant and extensively 
drug-resistant tuberculosis.
PNU 100480
PNU 100480 is an analog of linezolid that is being   developed 
for tuberculosis, and a Phase I trial is in progress.28 It 
has shown slightly better activity than linezolid against 
M.   tuberculosis in vitro, but substantially improved   activity 
in mouse models of tuberculosis.29 The combination of PNU-
100480, moxifloxacin, and pyrazinamide, which does not 
contain either rifampin or isoniazid, was also more active 
than rifampin, isoniazid, and pyrazinamide. These results 
suggest that PNU100480 may have the potential to shorten 
the duration of therapy significantly for drug-susceptible and 
multidrug-resistant tuberculosis.30,31
AZD 5847
AZD 5847 is anoxazolidinone, the chemical structure and 
preclinical study results for which have not been made 
  available to the public. However, a Phase I trial is going on, 
with an ascending dose study of the pharmacokinetics, safety, 
and tolerability of the compound.
Rifamycins
Recent renewed interest in high-dose rifamycins, includ-
ing daily rifapentine therapy, is a result of the integration 
of pharmacokinetic and pharmacodynamic principles 
into the development of antituberculous drugs. Since the 
introduction of rifampicin four decades ago, the rifamy-
cins have been cornerstone agents in the modern short-
course regimen due to their relatively strong sterilizing 
activity.32,33
Rifapentine is a congener with more potent in vitro 
activity than rifampicin (minimum inhibitory concentra-
tion 0.06 mg/mL versus 0.25 mg/mL)34 and a longer serum 
half-life (11–18 hours versus 2–4 hours).35,36 Its develop-
ment as an antituberculous drug was solely to provide 
an option for once-weekly supervised therapy during the 
continuation phase. Use of rifapentine at 7.5 or 10 mg/kg 
(corresponding to typical human doses of 450 or 600 mg) 
in daily regimens or 15 mg/kg (corresponding to typical 
human doses of 900 mg) in a three-times weekly regimen 
in combination with isoniazid and pyrazinamide shortened 
the treatment duration needed to prevent relapse by 50%.37 
Higher rifapentine doses were even more effective.37,38
The lone Phase III trial involving rifapentine includes two 
experimental arms in which initial-phase treatment is with 
rifampicin 10 mg/kg, moxifloxacin 400 mg, pyrazinamide, 
and ethambutol, while continuation-phase treatment is either 
twice-weekly rifapentine 15 mg/kg and moxifloxacin for 
2 months or once-weekly rifapentine 20 mg/kg and moxi-
floxacin for 4 months. Three Phase II trials will evaluate daily 
rifapentine-based regimens. A randomized, double-blind 
trial conducted by the US Centers for Disease Control and 
Prevention will evaluate the safety, tolerability, and efficacy 
of replacing rifampicin 10 mg/kg with rifapentine 10 mg/kg 
administered 5 days per week during the first 8 weeks of 
daily treatment. In a second trial conducted in South Africa, 
investigators from Johns Hopkins University and Cape Town 
University will evaluate the dose-response of two daily 
rifapentine doses (7.5 and 10 mg/kg) administered 7 days 
per week in place of rifampicin during the first 8 weeks of 
treatment. In a third trial, investigators from Johns Hopkins 
University and the Federal University of Rio de Janeiro 
will evaluate the efficacy of a daily regimen of rifapentine 
7.5 mg/kg combined with moxifloxacin, pyrazinamide, and 
ethambutol administered 7 days per week for the first 8 weeks 
in a trial conducted in Brazil. Rifapentine, in combination 
with isoniazid and pyrazinamide, shortened the treatment 
duration in a mouse model.39 In clinical trials of rifapentine 
used at approved doses, relapse rates are higher than with 
rifampin-containing regimens.40
Diarylquinoline
Diarylquinoline (TMC-207) is an ATP synthase inhibitor dis-
covered by high-throughput screening against   Mycobacterium 
smegmatis.4 It is highly potent against drug-susceptible and 
drug-resistant strains of M. tuberculosis. In June 2009,   Tibotec 
(a subsidiary of Johnson & Johnson) published preliminary 
stage 1 data from a double-blind, placebo-controlled, ran-
domized Phase II trial showing a reduced time to culture 
conversion and a higher number of culture conversions after 
8 weeks of a standard background regimen plus TMC207 in 
patients with multidrug-resistant tuberculosis. The compound 
was safe and well tolerated over the 8-week treatment period, 
and only nausea occurred significantly more frequently among 
patients in the TMC207 group than among those in the placebo 
group.41 In the second open-label Phase II trial, patients with 
newly diagnosed sputum smear-positive,   multidrug-resistant 
pulmonary tuberculosis have been enrolled. Enrollment 
has now concluded, with 234 patients enrolled, and pri-
mary data are expected to be available in 2011. The trial 
is expected to conclude in January 2013. There is some Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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evidence to suggest that TMC207 may affect antiretroviral 
drug levels, so Tibotec has carried out a Phase I, open-label, 
single-sequence, drug–drug interaction trial to investigate the 
pharmacokinetic interaction between steady-state nevirapine 
and single-dose TMC207 in HIV-infected subjects. The trial 
was completed in June 2010, but no results have been posted 
or published as yet. A similar but randomized crossover study 
of the interaction with lopinavir/ritonavir in healthy subjects 
has been completed by Tibotec. The National Institute of 
Allergy and Infectious Diseases has also completed a Phase I 
safety, tolerability, and pharmacokinetic interaction study of 
single-dose TMC207 and efavirenz in healthy volunteers, 
but no results are as yet available to the public. Tibotec is the 
only drug developer that has got approval from the European 
Medicines Agency for a pediatric development plan for future 
clinical studies of TMC207 in children to establish safe and 
effective dosing based on age and development.42
Nitroimidazole
This class of compounds can trace its history back to the 
1970s, when Ciba-Geigy in India investigated a series of 
nitroimidazoles for their potential role as   radiosensitizing 
agents.43 It was later discovered that many of these 
  compounds possessed antimicrobial activity, including 
activity against M. tuberculosis. However, when the 
lead compound (CGI-17341) was found to be mutagenic 
in the Ames assay, further development was halted.44 
Two members of this class (OPC-67683, PA-824) are cur-
rently in Phase II clinical trials for a tuberculosis indication 
and seem devoid of the mutagenicity that plagued many 
compounds in this class.45,46
PA-824
PA-824 was selected from a library of 700 newly synthesized 
nitroimidazo-oxazines (also described as nitroimidazopy-
rans) as the compound having the most potent activity in a 
murine model. Its minimum inhibitory concentration ranges 
from #0.015 to 0.25 mg/mL against susceptible strains, as 
well as strains resistant to the commonly used first-line and 
second-line drugs.45 PA-824 is a prodrug that is activated 
by a bacterial deazaflavin (F420)-dependent nitroreductase 
known as Ddn (Rv3547).47,48 The reactive intermediate(s) 
of PA-824 exert antituberculous activity via at least one 
novel mechanism, including inhibition of ketomycolic acid 
synthesis in the cell wall, inhibition of protein synthesis, and 
generation of intracellular nitric oxide.46,47 Like TMC207, 
PA-824 is active against nonreplicating persisters in the in 
vitro Wayne model46,49 and those selected by treatment of 
100-day-old cultures with or without high concentrations 
of rifampicin, indicating its significant sterilizing activity.50 
PA-824 demonstrates dose-dependent bactericidal and steril-
izing activity in a murine model of tuberculosis.49,51
Combination of PA-824 with rifampicin and pyrazin-
amide results in more rapid lung culture conversion than 
the standard first-line regimen of isoniazid, rifampicin, and 
pyrazinamide.52,53 The combination of PA-824 with moxi-
floxacin and pyrazinamide cures mice more rapidly than the 
first-line regimen, suggesting that PA-824 may be capable 
of shortening the duration of treatment of drug-susceptible 
as well as multidrug-resistant or extensively drug-resistant 
tuberculosis.54 Phase I studies demonstrated less than dose-
proportional increases in drug levels, reaching a plateau at 
600 mg in a multidose study. The maximal serum concen-
tration was 3.8 mg/mL and the elimination half-life was 
16–20 hours.55 A randomized, partially blinded Phase IIa 
extended early bactericidal activity trial has been conducted 
in South Africa to evaluate the dose-response of PA-824 in 
newly diagnosed patients with smear-positive pulmonary 
tuberculosis. There was no dose-response observed over the 
200–1200 mg dose range tested.56 While the lack of dose-
response for the 600–1200 mg doses may be explained by 
the abovementioned plateau in drug exposure, the lack of 
dose effect over the 200–600 mg dose range is surprising. 
A second 14-day dose-ranging early bactericidal activity 
trial evaluating PA-824 doses of 50, 100, 150, and 200 mg 
was completed in September 2010, but the results have not 
been published as yet.
OPC-67683
OPC-67683 is a dihydroimidazo-oxazole agent under 
development by Otsuka Pharmaceuticals specifically for 
the treatment of tuberculosis. Cross-resistance with PA-824 
occurs through mutations in Ddn, the enzyme responsible 
for activation.57 OPC-67683 is more potent than PA-824 in 
vitro and in vivo, with a minimum inhibitory concentra-
tion of 0.006–0.024 mg/mL and minimum bactericidal 
activity at 2.5 mg/kg in mice, resulting in a 2 log10 reduction 
in colony forming units,45 as compared with 50 mg/kg for 
PA-824 in a similar model by Nuremberger (unpublished 
observation). In a Phase I multidose investigation using 
two different formulations, OPC-67683 was administered 
in doses up to 400 mg. A 14-day extended early bactericidal 
activity trial has been performed with the newer formula-
tion of OPC-67683, but the results have not been reported 
in detail. A Phase IIb trial has been completed in patients 
with multidrug-resistant tuberculosis randomized to receive Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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an optimized background regimen with either OPC-67683 
at 100 or 200 mg twice daily or placebo in June 2010, with 
the first follow-up in October 2010, but no results have been 
reported thus far.
Pyrroles
The antituberculous activity of the pyrrole class was first 
described in 1998. The most potent of the compounds 
described at that time was BM212, with minimum inhibi-
tory concentrations that ranged from 0.7 to 1.5 mg/mL 
against several strains of M. tuberculosis. The minimum 
inhibitory concentrations for resistant strains are similar to 
those for   susceptible strains, suggesting a novel mechanism 
of action.58
LL-3858, also a pyrrole, was discovered in 2004. While 
the mechanism of action remains unknown, early reports 
described a minimum inhibitory concentration range of 
0.06–0.5 mg/mL that was not affected by resistance to isoniazid 
and rifampicin. Additive activity in combination with first-
line drugs in the murine model was also described.59 LL3858 
is being developed by Lupin and has been evaluated in a mul-
tidose Phase 1 trial involving healthy volunteers in India. An 
open-label Phase IIa trial to determine the early bactericidal, 
extended early bactericidal activity, and pharmacokinetics 
of LL-3858 for the treatment of newly diagnosed sputum 
smear-positive pulmonary tuberculosis has been completed, 
but the results are not available to the public.60
Diamine
SQ109, or N-adamantan-2-yl-N1-(3,7-dimethylocta-2,6-
dienyl)-ethane-1,2-diamine, is being developed by Sequella. 
Although originally intended to be an improvement on etham-
butol, a first-line tuberculosis drug, its structural dissimilarity 
to ethambutol and the potential differences in its intracellular 
target(s) suggest that it may be a truly novel antimycobacterial 
agent and not an analog of ethambutol. It has a minimum 
inhibitory concentration of 0.16–0.64 mg/mL, which does 
not appear to be affected by resistance to ethambutol. The 
mechanism of action of SQ109 remains to be fully elucidated. 
Inhibition of cell wall synthesis is implicated by the induc-
tion of Rv0341 but, in addition to the lack of evidence for 
cross-resistance, gene expression analysis suggests it may 
not be the same as seen with ethambutol.61,62
SQ109 is an orally active antibiotic for treatment 
of   pulmonary tuberculosis, Helicobacter pylori-related 
  duodenal ulcers and carcinomas, and Candida glabrata.63,64 
Currently in Phase II clinical trials, SQ109 could replace 
one or more drugs in the current   first-line tuberculosis 
drug   regimen, simplify therapy, and shorten the treatment 
  regimen.63 A multidose escalation study has been completed. 
In vitro metabolism studies using recombinant cDNA 
expressed human CYPs in conjunction with specific CYP 
inhibitors, indicating that CYP2D6 and CYP2C19 were the 
predominant CYPs involved in SQ109 metabolism, with 
little effect of CYP3A4.65
Dipiperidines
Dipiperidines comprise a series of compounds derived from 
a 25,000-compound library based on changing the ethylene 
bridge of 1,2 ethylenediamines. Many of these compounds 
contain a dipiperidine pharmacophore. Several compounds 
in the dipiperidine class demonstrated good activity against 
M. tuberculosis, low nonspecific   cytotoxicity, a   selectivity 
index indicative of a suitable therapeutic window, and 
good log P values (an in silico predictor of intestinal 
absorption).
The dipiperidine hits included an adamantane-containing 
hydroxydipiperidine, SQ609, which has been demonstrated 
to be the most promising compound of this class. SQ609 
is an orally active small-molecule antibiotic proposed for 
treatment of pulmonary tuberculosis and is currently entering 
preclinical safety, pharmacology, and toxicology studies as 
an investigational new drug. SQ609 is expected to increase 
the efficacy of the first-line drug regimen, simplify therapy, 
and/or shorten the treatment duration for drug-sensitive 
and drug-resistant tuberculosis. As per the statement by 
its developer, Sequella, SQ609 has unique characteristics 
that may give it the potential to be an important new tool 
in the treatment of both drug-sensitive tuberculosis, as 
well as multidrug-resistant and extensively drug-resistant 
tuberculosis.
A summary of its attributes includes:
•	 Potent in vitro activity against laboratory and clinical 
strains of M. tuberculosis
•	 Inhibition of M. tuberculosis by interfering with cell wall 
biosynthesis
•	 Moderate in vitro cytotoxicity in cultured mammalian 
cells
•	 A suitable therapeutic window in vitro
•	 Activity against intracellular M. tuberculosis
•	 Activity against single-drug resistant strains of M. tuber-
culosis (isoniazid, rifampin, and streptomycin)
•	 High specificity for M. tuberculosis
•	 Good aqueous solubility
•	 Oral activity by itself in two different mouse models of 
tuberculosisClinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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•	 Ability to prolong the therapeutic effect after withdrawal 
of single and multiple drugs during therapy in mice
•	 Activity better than tuberculosis standard of care (1–2 
log10) when administered in combination with isoni-
azid, rifampin, and pyrazinamide in murine models of 
tuberculosis
•	 Favorable in vitro safety, pharmacology, and absorption, 
distribution, metabolism and excretion profile.66
Capuramycins
SQ641, a semisynthetic antibiotic, is the lead drug candidate 
selected from a 7000-compound library of semisynthetic 
nucleoside-based translocase 1 (TL-1) inhibitors developed 
as potential treatments for bacterial infections. It is particu-
larly active against M. tuberculosis causing tuberculosis, 
nontuberculous mycobacterial pneumonia, pneumonia 
caused by Streptococcus pneumoniae, Crohn’s disease, 
and   Staphylococcus aureus, including the methicillin-
resistant strain that causes skin and soft tissue infections. 
The capuramycin class of antibacterial antibiotics inhibits 
the TL-1 enzyme which is essential for construction of the 
cell wall and is present only in bacteria. Because the TL-1 
enzyme is absent in eukaryotic cells, it is an attractive target 
for antibiotic development. Despite the ubiquity of TL-1 in 
bacteria, capuramycin and its analogs, including SQ641, 
are remarkably specific for Mycobacteria and certain 
  Gram-positive bacteria, making it a promising candidate 
for a future regime. Attributes of SQ641 as described by the 
developer (Sequella)67 include:
•	 Killing M. tuberculosis faster than any existing antitu-
berculosis drugs, including isoniazid and rifampin
•	 Activity against all strains of multidrug-resistant clinical 
strains of M. tuberculosis tested to date
•	 An exceptional 55-hour post-antibiotic effect against 
M. tuberculosis
•	 Strong synergy with ethambutol, streptomycin, and 
SQ109 (the manufacturer’s lead antituberculosis drug, 
currently completing Phase 1B clinical trials)
•	 Strong efficacy in preventing development of   drug-resistant 
mutants of M. tuberculosis
•	 Excellent in vitro activity against nontuberculous 
  Mycobacteria, ie, M. avium complex, M. abscessus, and 
M. kansasii, as well as the M. avium subspecies para-
tuberculosis, the etiologic agent of Johne’s disease (and 
suspected etiologic agent of Crohn’s disease),
•	 Synergism with a variety of agents having activity against 
nontuberculous Mycobacteria.67
isothiazoloquinolones
Isothiazoloquinolones are an underexplored chemotype 
related to quinolones, first described by Chu et al and 
Abbott in the late 1980s.68,69 Isothiazoloquinolones have 
a substitution in the typical 3-carboxyl group by an iso-
thiazolone ring and have demonstrated good antibacterial 
activity.70,71
ACH-702 is a lead isothiazoloquinolone compound, 
the activity of which has been studied against a number of 
bacterial pathogens, including methicillin-resistant S. aureus 
(MRSA) and vancomycin-resistant Enterococcus, with prom-
ising results.70–72 Analogs of the quinolone class, these com-
pounds target bacterial replication and are potent   inhibitors 
of both DNA gyrase and topoisomerase IV .73
ACH-702 has a novel target profile against bacterial DNA 
replication enzymes and potent broad-spectrum   bactericidal 
activity, characteristics which may play an important role in 
the fight against drug-resistant bacteria.74 Minimum inhibi-
tory concentration assays of ACH-702 against clinical isolates 
of M. tuberculosis, including drug-resistant isolates, and 
additional isolates of nontuberculous Mycobacteria, have 
shown comparable or superior activity to moxifloxacin in 
most cases.75 ACH-702 is also effective against fluoroqui-
nolone-resistant isolates of M. tuberculosis, consistent with 
its antibacterial activity against fluoroquinolone-resistant 
isolates of other bacteria.76
Caprazene nucleosides
CPZEN-45 is a nucleoside antibiotic that is soluble in 
water at .10 mg/mL as the trifluoroacetate salt. It is a 
caprazamycin produced by Streptomyces spp, and was 
first described in 2003 by researchers at the Microbial 
Chemistry Research Foundation and Meiji Seika Kaisa 
Ltd in Japan. CPZEN-45 has a minimum inhibitory con-
centration of 1.56 µg/mL against M. tuberculosis H37Rv 
and 6.25 µg/mL against a multidrug-resistant strain of M. 
tuberculosis. This compound is active against both replicat-
ing and nonreplicating M.   tuberculosis in vitro, suggesting 
it could be efficacious against latent organisms in vivo. 
CPZEN-45 has shown efficacy against both drug-sensitive 
and extensively drug-resistant M. tuberculosis in a mouse 
model of acute tuberculosis, in which animals were infected 
by intravenous injection and treated with subcutaneous 
administration of CPZEN-45. Improved efficacy against 
drug-sensitive M. tuberculosis was shown when CPZEN-45 
was administered in combination with other antitubercu-
lous drugs.77Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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Benzothiozinones and dinitrobenzamide
These agents were found to be highly active against resistant 
and sensitive strains of M. tuberculosis, including extensively 
drug-resistant and multidrug-resistant strains. Both BTZ043 
(a benzothiozinone) and dinitrobenzamide drugs have the 
same target, ie, heterodimeric decaprenylphosphoryl-D-
ribose 2I-epimerase, encoded by the dprE1(Rv3790) and 
dprE2(Rv3791) genes,78 thereby blocking arabinogalactan 
and lipoarabinomannan synthesis in the mycobacterial cell 
wall and growth of M. tuberculosis.79
To monitor for potential development of benzothiazinone 
resistance, a total of 240 sensitive and multidrug-resistant 
M. tuberculosis clinical isolates from four European hospitals 
were surveyed for the presence of mutations in the dprE1 gene 
and for benzothiazinone susceptibility. All 240 strains were 
susceptible, thus establishing a baseline prior to the introduc-
tion of BTZ043 in clinical trials.80 The EPFL School of Life 
Sciences is the current developer of this drug that has now 
entered Phase I clinical investigation in humans.
imidazopyridine
Q201 is a compound undergoing preclinical investigation at 
Quro Science in Korea as of 2010, and is expected to enter 
Phase I study by 2011, although no information about the 
drug has been made available to the public.81,82
Riminophenazines
Riminophenazines were discovered in the 1970s and were 
proposed as a probable solution to multidrug-resistant 
  tuberculosis as early as 1999.83 They have been effective in 
treating leprosy, although existing compounds have poor 
solubility and side effects, such as pronounced skin discolor-
ation. In 2007, the TB Alliance, in partnership with the Insti-
tute of Materia Medica in Beijing, designed and synthesized 
more efficacious compounds in this promising class.
Riminophenazines are thought to inhibit the energy 
metabolism needed even in slow-growing M. tuberculosis 
persisters, and therefore show promise for shortening the 
duration of treatment. They show no cross-resistance with 
any other class of antituberculous drugs, and are therefore 
potential agents for treating drug-resistant tuberculosis. Their 
lack of intrinsic CYP interactions would make them safe to 
coadminister with antiretrovirals in patients coinfected with 
tuberculosis and HIV .84 Within the first year, the project team 
designed four series of molecules with pharmacophores 
which were distinct from that of   clofazimine. These com-
pounds were tested in vitro and in vivo for activity against 
M. tuberculosis and in various absorption, distribution, 
metabolism, elimination, and toxicity assays. Phenoxazine 
and an asymmetrical riminophenazine series showed both 
potent activity and improved physicochemical properties.84
The Stop TB strategy
As part of the millennium development goals, targets endorsed 
by the Stop TB Partnership had aimed to detect at least 70% 
of new sputum smear-positive tuberculosis cases and cure 
at least 85% of these cases by 2005, to reduce tuberculosis 
prevalence and death rates by 50% relative to 1990 by 2015, 
and to eliminate tuberculosis as a public health problem (less 
than one case per million population) by 2050. Realizing the 
inadequacies of the program as evaluated in 2005, the Stop 
TB Strategy was devised by the WHO in 2006 with a vision of 
a world free of tuberculosis. The goal was to reduce the global 
burden of tuberculosis by 2015 dramatically, in keeping with 
the previously set targets. The objectives are to achieve uni-
versal access to high-quality diagnosis and patient-centered 
treatment, to reduce the suffering and socioeconomic burden 
associated with tuberculosis, to protect poor and vulnerable 
populations from the disease, coinfection with tuberculosis 
and HIV , and multidrug-resistant tuberculosis, as well as to 
support development of new tools and enable their timely and 
effective use. One important component of the program is to 
promote research to develop new drugs, vaccines (Table 2), 
and diagnostics (Table 3).85
Table 2 TB vaccine constructs in phase ii clinical trials (as of July 2011)
Agent Strategy Type Sponsors Status
MVA85A/ 
AeRAS-485
Prime boost Viral vector Oxford-emergent 
Tuberculosis Consortium, Aeras
Phase iib
AeRAS-402/ 
Crucell Ad35
Prime boost Viral vector Crucell N.V., Aeras Phase iib
GSKM72 Prime boost Recombinant protein GSK Biologicals, Aeras Phase ii
RUTi immunotherapeutic Fragmented MTB Archivel farma Phase ii
Note: Reproduced with permission from the Treatment Action Group (http://www.treatmentactiongroup.org/pipeline-report/2011).
Abbreviations: GSK, GlaxoSmithKline; MTB, Mycobacterium tuberculosis.Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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Tuberculosis vaccination  
in the pipeline
The existing tuberculosis vaccine, Bacille Calmette-Guérin 
(BCG), is only partially effective and is contraindicated in 
HIV coinfection. A novel tuberculosis vaccine or regimen is 
a key component of the Stop TB Strategy. Target populations 
for a tuberculosis vaccine are adults, adolescents, children, 
and infants in high-burden countries, including   individuals 
with HIV coinfection or latent tuberculosis infection. 
  Ongoing clinical trials of BCG are evaluating modifications 
to the current vaccination methods. Prophylactic tuberculosis 
vaccines in clinical trials are live mycobacterial vaccines 
designed to replace the BCG or subunit vaccines designed 
to boost BCG.86
Current tuberculosis vaccine candidates are designed to 
contain the tuberculosis bacillus by enabling the immune 
system to get a “head start” when exposed, reducing the bac-
terial load and preventing progression to clinical disease,87,88 
without inducing sterilizing immunity or, in other words, to 
prevent infection altogether. Clinical development of a new 
tuberculosis vaccine is dependent upon validation in animal 
models of safety, toxicology, and efficacy, and the identifica-
tion of biomarkers of protection. The most advanced candi-
date vaccines are currently in Phase IIb trials. Field sites in 
high-burden countries are required for large-scale efficacy 
and licensure trials.86
M72 is a recombinant protein vaccine made up of an 
adjuvant molecule that stimulates an immune response, and 
two recombinant tuberculosis proteins intended to strengthen 
the immune response to two highly immunogenic fragments 
of the tuberculosis bacillus. Early results suggest that the 
vaccine is clinically well tolerated and produces a measur-
able immune response.89 Subsequent clinical trials are now 
planned for adolescents and infants in tuberculosis-endemic 
regions.90
AERAS-402/Crucell Ad35 from Crucell NV and Aeras is 
an adenovirus 35 (Ad35) modified to include specific tuber-
culosis antigens to trigger an immune response. A series of 
Phase I studies has demonstrated tuberculosis-specific CD4 
and CD8 responses in BCG-naive and BCG-vaccinated adult 
volunteers after receiving the vaccine. A Phase II clinical 
trial in adults recently treated for pulmonary tuberculosis 
and a Phase I study in infants are ongoing. A Phase IIb 
randomized, placebo-controlled, proof-of-concept study in 
HIV-positive adults with CD4 counts .350 was recently 
initiated to evaluate the safety and efficacy of AERAS-402/
Crucell Ad35.89
MVA85A/AERAS-485 is a live viral-vectored vaccine 
that is an attenuated version of the vaccinia virus combined 
with tuberculosis antigen 85A. The first infant received a 
dose in July 2009 as part of a Phase IIb proof-of-concept 
study. This is the first time in over 80 years that a vaccine has 
Table 3 TB Diagnostic Test or Processes in the Pipeline, 2011
Name of test Sponsor/Developer Technique What it measures Estimated date 
of WHO review
Peripheral laboratories
Manual loop-mediated 
isothermal amplification 
process (LAMP)
eiken Chemical/Foundation 
for innovative New 
Diagnostics (FiND)
Manual nucleic acid amplification MTB DNA 2012
Clearview® TB eLiSA Alere eLiSA to detect Lipoarabinomannan 
(LAM) in urine
MTB LAM antigen 2013
Colorimetric Thin 
Layer Agar (TLA) DST
London School of Hygiene 
and Tropical Medicine/
FiND
Colorimetric DST by culturing 
TB on a TLA plate and using 
microscopy to identify MTB growth
MTB culture growth 2012
Reference laboratories
GenoType® MTBDRs Hain Lifescience/FiND Line probe assay to identify drug 
susceptibility to second-line TB 
drugs on TB culture isolate; is 
being tested on sputum samples
MTB DNA indicating resistance 
to fluoroquinolones, ethambutol, 
and aminoglycosides/cyclic 
peptides (amikcin, kanamycin, 
capreomycin)
2012
Sensititre® MTB 
minimum inhibitory 
concentration 
(MiC) Plate
TReK Diagnostic Systems Detects MTB growth in TB 
antibiotic containing plates to 
identify drug resistance
TB bacilli 2013
Note: Reproduced with permission from the Treatment Action Group (http://www.treatmentactiongroup.org/pipeline-report/2011).
Abbreviations:  DST,  drug  susceptibility  testing;  eLiSA,  enzyme  linked  immunosorbent  assay;  DNA,  deoxyribonucleic  acid;  TB,  tuberculosis;  MTB,  Mycobacterium 
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been tested for efficacy in infants.91 The trial is comparing 
MVA85A versus placebo in BCG-vaccinated, HIV-negative 
infants. The first results are expected in 2012.86 RUTI is a 
killed TB vaccine that was originally discovered at Institut 
Germans Trias i Pujol and is now being developed by the 
biotech company Archivel Farma. The vaccine is being evalu-
ated for its potential to accelerate the treatment of latent TB 
infection in combination with isoniazid. It has a potential 
for reducing risk of isoniazid resistance by shortening the 
duration of therapy.92 Seven more candidates are being tested 
clinically in a Phase I trial including recombinant live and 
other types of vaccines and one Mycobacterium vaccae-
inactivated whole cell nontuberculous mycobacterial vaccine 
has undergone Phase III investigation. There are six candi-
dates undergoing preclinical studies, and 22 next-generation 
candidates are being developed.92
Diagnostic pipeline for tuberculosis
Despite significant progress at a level suitable for reference or 
peripheral laboratories, investment in the research necessary 
to discover and develop a true point-of-care test for tuber-
culosis is shockingly inadequate. There is no peer-reviewed 
information available about a diagnostic tool that is likely to 
be approved by the Who Strategic and Technical Advisory 
Group for Tuberculosis in the next three years for use at the 
health post.93 The Eiken loop-mediated isothermal amplifica-
tion process (LAMP) nucleic acid test and Clearview lipoara-
binomannan antigen enzyme-linked immunosorbent assay 
test could be performed in peripheral laboratories. Lower 
sensitivity of sputum-negative cases in the LAMP test and 
in patients with HIV coinfection and a CD4 count .200 in 
a lipoarabinomannan enzyme-linked immunosorbent assay 
test have led to uncertainty about the significance of these 
noninvasive and relatively rapid tests.
GeneXpert MTB/RIF, a reference laboratory test, is 
highly sensitive as well as specific in smear-positive cases 
and could also identify rifampicin-resistant strains. The test 
requires minimal training of laboratory workers and provides 
results within 2 hours. Because it is a closed-system test, it 
does not require laboratories with high levels of biosafety 
and has low contamination concerns. However, the prohibi-
tive costs of the kit and instruments are an impediment to its 
widespread application.94
Interferon-gamma release assays
The three interferon-gamma release assays available on 
the market are the QUANTIFeron Gold test (QFT-G) 
and QUANTIFeron Gold in a Tube test (QFT-GIT), both 
produced by Cellestis (Valencia, CA), and T-SPOT.TB 
from Oxford Immunotec (Marlborough, MA). These tests 
are immune-based tests for latent tuberculosis infection. 
BCG vaccination does not cause false positives in the 
  interferon-gamma release assay, as is often the case with the 
tuberculin skin test. The first and second tests require samples to 
be processed within 16 hours on an enzyme-linked immunosor-
bent assay format, which prevents them from being used in 
health facilities at levels below reference laboratories. The 
tests have moderate sensitivity. The third tuberculosis test 
(T-SPOT) requires that the sample be processed in 8 hours 
and needs a greater degree of sample processing.94
The diagnostic pipeline for tuberculosis has yielded a 
group of new tools that have addressed important gaps in the 
current armamentarium, although they have not yet translated 
into any significant measurable improvement in tuberculosis 
case detection or treatment outcomes, mainly because they 
are not appropriate for peripheral health post settings in 
low-income countries where most people with tuberculosis 
access their care.95
Improved diagnostics and incorporation of potent bac-
tericidal as well as sterilizing agents into antituberculous 
regimens should make the prognosis of multidrug-resistant 
and extensively drug-resistant tuberculosis much better, 
and emergence of new multidrug-resistant or extensively 
drug-resistant strains a   rarity, at least in theory. However, 
keeping in mind the failure of conventional first-line drugs 
that theoretically should have been effective in 95% of cases, 
other regulatory and administrative challenges, economic 
constraints leading to suboptimal therapy, uncontrolled drug 
usage in the private sector allowing unscientific combina-
tions and undertreatment facilitating emergence of resistant 
strains, and irresponsible overtreatment or retreatment, must 
also be addressed. After investing billions of dollars in drugs, 
lack of control over implementation of ideal and adequate 
regimens and irresponsible usage in the private sector, which 
has a 60% share of the world antituberculous drug market, 
would pose a risk of losing these drugs to resistance quickly, 
without exploiting their full potential to achieve the goals of 
the Stop TB program.96
Strategies to develop new antituberculous drugs include 
screening libraries of small molecules and natural prod-
ucts, as well as prior identification of targets crucial to the 
micro-  organism and subsequent design of new molecules. 
  Development of new drugs from known compounds which 
have already shown safety and efficacy is an attractive 
strategy from the economical, pharmaceutical, and clinical 
points of view.95Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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Innovative approaches
Kinnings et al developed a chemical systems approach 
to identify off-targets of major pharmaceuticals on a 
  proteome-wide scale and showed that entacapone and 
tolcapone, presently used in the treatment of Parkinson’s 
disease, have the potential to treat multidrug-resistant and 
extensively drug-resistant tuberculosis.97 These drugs are 
predicted to bind to the InhA enzyme and directly inhibit 
substrate binding. The minimum inhibitory concentra-
tion of entacapone for M. tuberculosis is approximately 
260.0 µM,99 which is well below the toxicity concentra-
tion determined by an in vitro cytotoxicity model using a 
human neuroblastoma cell line. Thus, the active compo-
nent in entacapone represents a promising lead compound 
for developing a new class of antituberculous therapeutics 
with an excellent safety profile, and incorporating a simi-
lar approach might discover novel drugs with a similar 
safety profile.97
Thioridazine
Thioridazine, a known phenothiazine neuroleptic, has been 
shown to modulate the expression of genes encoding mem-
brane proteins and efflux pumps, as well as oxidoreductases 
and other enzymes involved in fatty acid metabolism and 
aerobic respiration.98 Because thioridazine targets multiple 
pathways, including those involved in cell wall processes 
and respiratory chain components, it may serve as a model 
for multitarget drug development, as well as constitute a 
highly potent addition to a combination of antituberculous 
drug regimens for the management of multidrug-resistant 
and extensively drug-resistant disease.99 Thioridazine was 
used to cure 10 of 12 patients with extensively drug-resistant 
tuberculosis in Buenos Aires, Argentina. It is being used for 
compassionate treatment of terminal patients with extensively 
drug-resistant tuberculosis nonresponsive to antibiotics in 
Mumbai, India.100
Capreomycin
Capreomycin, an ideal second-line drug for multidrug-
resistant tuberculosis, has seen a setback with the emergence 
of capreomycin-resistant cases due to single gene mutations 
in Mycobacteria. Detailed characterization of capreomycin 
targets by data mining was undertaken to construct an inter-
action topology of the M. tuberculosis genes responsive to 
capreomycin. Integrating genes, small metabolites, proteins, 
and underlying signaling pathways to shed light on the 
physiology, pathogenesis, and network of pathogen responses 
have been emerging, and show great promise for unravelling 
the intricate drug action involved. Dampening of virulence 
factors and the aerobic respiratory rate of M. tuberculosis 
might be the new targets of capreomycin beyond Rv1364c, 
pe_pgrs38, and pe_pgrs51, which are the salient nodes of 
the network and thus the most promising new capreomycin 
targets meriting further exploration.101
Fosmidomycin
2C-methyl-d-erythritol 4-phosphate (MEP) lacks homolo-
gous enzymes in the human host, so is a vital pathway in 
M. tuberculosis, is amenable to bacterium-specific drug target-
ing, and shows potential for identification of lead compounds 
unencumbered by target-based toxicity. Fosmidomycin is 
now known to inhibit the second step in the MEP pathway. 
High-throughput screening campaigns in the search for new 
compounds that manipulate enzymes of the MEP pathway 
may discover molecules effective against multidrug-resistant 
and extensively drug-resistant tuberculosis.102
Guanosine triphosphatases
Guanosine triphosphatases have been noted to have a crucial 
role in the survival and pathogenesis of various pathogens 
by interference in the arrest of phagosome maturation, 
enabling pathogens to survive by escaping from lysozymes 
and toxic free radicals, enabling M. tuberculosis to evade the 
host defense system, which contributes to its virulence. This 
observation provides a new avenue for the development of 
antituberculous drugs.103
Antituberculous compounds from natural sources have 
an enormous potential for new drug development. Some 
of these have demonstrated not only antimicrobial activity 
per se but also inhibition of the mechanism of resistance 
(eg, efflux pumps) or modulation of the immune response 
(eg, macrophage stimulation).96
Herbal agents
Dihydro-β-agarofuran sesquiterpene, (1α-acetoxy-6β,9β-
dibenzoyloxy-dihydro-β-agarofuran) isolated from   Celastrus 
vulcanicola exhibited antituberculous activity against the 
multidrug-resistant tuberculosis strain with a minimum 
inhibitory concentration of 6.2 µg/mL, comparable with 
or better than that for isoniazid or rifampin, which are 
two of the best first-line drugs commonly used to treat 
tuberculosis.104
Aristolochia taliscana is a plant used in traditional 
Mexican medicine to treat cough and snake bites. Biogu-
ided fractionation of hexanic extract led to the isolation of 
neolignans licarin A, licarin B, and eupomatenoid-7, all of Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
63
Drug development for resistant TB
which have antimycobacterial activity. Licarin A was the 
most active compound, with a minimum inhibitory concen-
tration of 3.12–12.5 µg/mL against several M. tuberculosis 
strains, including H37Rv, four monoresistant H37Rv   variants, 
and 12 clinical multidrug-resistant isolates, as well as five 
  nontuberculous mycobacterial strains.105
Essential oils of Myrtus communis L. are gaining 
remarkable interest for their potential multipurpose use 
as antioxidant, antibacterial, and antiseptic agents, and 
have been used in the past for the treatment of other lung 
diseases. The results for myrtle oil show good activity 
against M. tuberculosis but not against M. paratuberculosis. 
The minimum inhibitory concentration registered against 
M. tuberculosis was 0.17% (v/v) in comparison with a 
minimum inhibitory concentration of 2% (v/v) observed 
against M. paratuberculosis.106
Crude extracts of Aloe vera, Adhatoda vasica, and Allium 
sativum against multidrug-resistant isolates confirm earlier 
results, and activity of extracts of Acalypha indica and Allium 
cepa has been reported for the first time. Further studies 
aimed at isolation and identification of active substances 
from extracts showing promising activity now need to be 
carried out.107
Curcuma longa and Tinospora cordifolia formulations 
have been used as an adjuvant to conventional antitubercu-
lous treatment to prevent hepatotoxicity as well as to study 
their effects on the course of complicated tuberculosis. 
In multidrug-resistant nonresponders to DOT therapy, an 
extended course of first-line antituberculous treatment and 
herbs achieved a good clinical, radiological, and bacteriologi-
cal response in 68% of cases.108
Surgical measures
It is surprising that surgical measures as an option or possi-
bility for multidrug-resistant and extensively drug-resistant 
tuberculosis treatment have never been incorporated in 
strategic planning by any responsible body. However, 
promise of a cure in hopeless cases is not altogether absent 
in the peer-reviewed literature. Careful patient selection 
with adequate preoperative evaluation, ie, localized cavitat-
ing disease involving extensively drug-resistant or totally 
drug-resistant strains, and documented failure of optimal 
medical therapy, could ensure a superior outcome using 
an appropriate surgical resection procedure, although there 
is considerable risk of early postoperative morbidity.109–111 
In view of recent evidence showing that the risk of primary 
infection with multidrug-resistant or extensively drug-
resistant M. tuberculosis strains is growing, the surgical 
option looks to be attractive in carefully selected patients, 
where the median time to postoperative sputum smear 
and culture conversion has been reported to be 2 (range 
1–23) days.109
Novel drug delivery systems
The use of liposomes, polymeric microparticles, and 
  nanoparticles as inhalable antituberculous drug carriers has 
been investigated.112 Nanoparticles in particular have emerged 
as a remarkably useful tool for this purpose due to their high 
stability, feasibility of incorporation of both hydrophilic and 
hydrophobic substances, and ease of oral and inhalational 
administration in addition to parenteral administration. 
  Nanoparticles may also be useful to deliver drugs selec-
tively to monocytes, macrophages, or the reticuloendothelial 
  system, where dormant persistent organisms responsible for 
lengthy treatment periods may be lodging.15
Dry powder inhalers and nebulizers are another approach 
being tested.112 Dry porous particle aerosols of PA-824 
have been tested in low and high (eight-fold higher than 
the oral dose) dosages and compared with oral administra-
tion of PA-824 for treatment of tuberculosis in guinea pigs. 
The results show a lower degree of inflammation, bacterial 
load, and tissue damage, suggesting a potential role for 
these inhalational agents in the treatment of tuberculosis.113 
  Capreomycin, a second-line drug, is being tested as an inha-
lational product in the form of large porous particles admin-
istered to human volunteers in a Phase I study.   Inhalational 
approaches deliver much higher doses of drug to the lung, 
but the exact histological localization of the increased 
delivery is not clear.15 Cost of goods and training of health 
care providers and patients in efficient usage and prevention 
of cross-infection by instruments are the main obstacles to 
wider application, compounded by ambiguous evidence of 
superior efficacy for such a regimen.
Predictive biomarkers
In the absence of reliable biomarkers, we need to continue per-
forming large and lengthy Phase III trials with 12–24 months 
of follow-up after treatment for cure or relapse, which is a 
real obstacle to devising novel regimens with newer drugs in 
various combinations for multidrug-resistant or extensively 
drug-resistant tuberculosis. A predictive biomarker could 
greatly reduce the duration and number of patients needed 
in trials and hasten the development of new tuberculosis 
regimens.4 A reliable biomarker would be able to assess the 
activity and extent of disease, response to treatment, treat-
ment outcome (cure or relapse), anticipated poor clinical Clinical Pharmacology: Advances and Applications 2011:3 submit your manuscript | www.dovepress.com
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outcomes (so that treatment can be modified appropriately), 
and endpoints of novel antituberculous drugs.114 Currently 
the WHO and the European Commission have undertaken a 
joint biomarker study, and their report published in 2008 has 
recommended further research on microbiological markers 
like microbiological load, quantitative sputum   microbiology 
study, mycobacterial antigens 85 and 85B, mycobacterial 
DNA fragments, lipoarabinomannan and other protein 
antigens in urine, and volatile mycobacterial markers in 
breath. Host markers involve interferon-gamma release 
assays, antibodies to mycobacterial enzymes, and 38 kDa 
antigen, interferon gamma measured in sputum, soluble 
intercellular adhesion molecule type 1, neopterin (catabolic 
product of guanosine triphosphate), erythrocyte sedimenta-
tion rate, C-reactive protein, soluble urokinase plasminogen 
activator receptor (mainly expressed by macrophages and 
monocytes), host proteins like LAG-3V3, sCD30, total Ig E, 
chemokine CCL22, the IL-4/IL-4δ2 ratio, and whole blood 
killing assays.
Advanced technological platforms like transcriptomics, 
proteomics, and metabolomics have been envisaged for future 
development of ideal biomarkers, although analysis and inte-
gration of data from transcriptomic, proteomic, and metabolo-
mic investigations would be required to understand the “bigger 
picture” of the response and outcome of antituberculous 
treatment. Highly skilled bioinformaticists would be required 
to interpret the enormously complex data sets before the 
results could be put into a biological context.114
The Critical Path to New  
TB Regimens
In the absence of surrogate markers, the conventional 
approach to drug combination development evaluates poten-
tial compounds sequentially, substituting them individually 
into the existing regimen. Each alteration is studied in clini-
cal trials, which take at least six years to complete, so any 
regimen of new drugs would require at least 24 years of 
development. To overcome this challenge, the TB Alliance 
is promoting a new paradigm for tuberculosis drug devel-
opment, known as the Critical Path to New TB Regimens. 
Under this new approach, each potential drug compound 
would be assessed individually in Phase I and early bacterial 
activity trials. At the same time, potential combinations would 
be evaluated in preclinical models. This would first involve 
identifying the potential for any two agents to have synergistic 
and antagonistic effects against M. tuberculosis in vitro, under 
both replicating and nonreplicating conditions, in the labora-
tory. Potential drug combinations would then be evaluated in 
vivo for potential pharmacokinetic interactions, and priori-
tized for efficacy studies in mice. Promising combinations 
with significant efficacy would be further evaluated for their 
sterilizing activity. When up to five combinations have been 
identified with the potential for shortening therapy to less 
than 3 months, the two or three most effective combinations 
would be confirmed in a secondary animal infection model. 
The most effective new regimens would then be moved into 
human Phase I trials for pharmacokinetic interaction and 
safety studies in healthy volunteers, followed by Phase II and 
III trials that may shorten the regimen development time to 
around 6 years.115
Conclusion
Emerging options including novel regimens developed from 
the antituberculous drug pipeline, rapid diagnostic tools, and 
before and after exposure vaccines for tuberculosis will fail 
to make a significant impact if they are not accompanied by 
proper support from local health care systems, both public 
and private, as well as control measures from governmental 
authorities. Ensuring proper access to these tests, vaccines, 
and new drug regimens by patients most in need in resource-
poor countries should be taken up as a challenge by the WHO, 
as well as the international health care community, to achieve 
the desired outcome.
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